» Articles » PMID: 38214568

New Light on the HLA-DR Immunopeptidomic Landscape

Overview
Journal J Leukoc Biol
Date 2024 Jan 12
PMID 38214568
Authors
Affiliations
Soon will be listed here.
Abstract

The set of peptides processed and presented by major histocompatibility complex class II molecules defines the immunopeptidome, and its characterization holds keys to understanding essential properties of the immune system. High-throughput mass spectrometry (MS) techniques enable interrogation of the diversity and complexity of the immunopeptidome at an unprecedented scale. Here, we analyzed a large set of MS immunopeptidomics data from 40 donors, 221 samples, covering 30 unique HLA-DR molecules. We identified likely co-immunoprecipitated HLA-DR irrelevant contaminants using state-of-the-art prediction methods and unveiled novel light on the properties of HLA antigen processing and presentation. The ligandome (HLA binders) was enriched in 15-mer peptides, and the contaminome (nonbinders) in longer peptides. Classification of singletons and nested sets showed that the first were enriched in contaminants. Investigating the source protein location of ligands revealed that only contaminants shared a positional bias. Regarding subcellular localization, nested peptides were found to be predominantly of endolysosomal origin, whereas singletons shared an equal distribution between the cytosolic and endolysosomal origin. According to antigen-processing signatures, no significant differences were observed between the cytosolic and endolysosomal ligands. Further, the sensitivity of MS immunopeptidomics was investigated by analyzing overlap and saturation between biological MS replicas, concluding that at least 5 replicas are needed to identify 80% of the immunopeptidome. Moreover, the overlap in immunopeptidome between donors was found to be very low both in terms of peptides and source proteins, the latter indicating a critical HLA bias in the antigen sampling in the HLA antigen presentation. Finally, the complementarity between MS and in silico approaches for comprehensively sampling the immunopeptidome was demonstrated.

Citing Articles

Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics.

Carter P, Quarmby V Nat Rev Drug Discov. 2024; 23(12):898-913.

PMID: 39424922 DOI: 10.1038/s41573-024-01051-x.


Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG antibodies.

Tsai W, Li Y, Yin Z, Tran P, Phung Q, Zhou Z MAbs. 2024; 16(1):2362789.

PMID: 38845069 PMC: 11164226. DOI: 10.1080/19420862.2024.2362789.

References
1.
Almagro Armenteros J, Sonderby C, Sonderby S, Nielsen H, Winther O . DeepLoc: prediction of protein subcellular localization using deep learning. Bioinformatics. 2017; 33(24):4049. DOI: 10.1093/bioinformatics/btx548. View

2.
Abelin J, Harjanto D, Malloy M, Suri P, Colson T, Goulding S . Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction. Immunity. 2019; 51(4):766-779.e17. DOI: 10.1016/j.immuni.2019.08.012. View

3.
Attermann A, Barra C, Reynisson B, Schultz H, Leurs U, Lamberth K . Improved prediction of HLA antigen presentation hotspots: Applications for immunogenicity risk assessment of therapeutic proteins. Immunology. 2020; 162(2):208-219. PMC: 7808146. DOI: 10.1111/imm.13274. View

4.
Purcell A, Ramarathinam S, Ternette N . Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics. Nat Protoc. 2019; 14(6):1687-1707. DOI: 10.1038/s41596-019-0133-y. View

5.
Mellacheruvu D, Wright Z, Couzens A, Lambert J, St-Denis N, Li T . The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat Methods. 2013; 10(8):730-6. PMC: 3773500. DOI: 10.1038/nmeth.2557. View